SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2024 after the stock market closes on Tuesday, Feb. 27. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s investor relations website. A recording of the call will also be available on the website for 90 days. About Agilent Te ...

Over the past 80 years, the United States faced a persistent issue of in-state manufacturing decline, marked by a shift towards research and development rather than domestic production. The trend led to a significant loss of manufacturing jobs, peaking in the 2000s with a 33% decrease. However, technology is now reshaping U.S. manufacturing, offering a modern and advanced system. Investing in this upward trend, with an expected 5.2% rise in wages and benefits, can usher in a prosperous new era for American ...

To boost capabilities in protein analysis, Agilent Technologies (A) announced the launch of the Agilent ProteoAnalyzer system.The Agilent ProteoAnalyzer system is a new automated parallel capillary electrophoresis system for protein analysis that brings more efficiency, versatility and reliability in protein QC workflows by automating the separation, data processing and simplifying sample preparation steps.This way, it analyzes complex protein mixtures seamlessly.It is designed to analyze different sizes an ...

Investors looking for stocks in the Electronics - Testing Equipment sector might want to consider either Fortive (FTV) or Agilent Technologies (A) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks wi ...

ValeryEgorov Step one: Wide-moat stocks with 5-star and 4-star ratings Historical evidence says that while quality alone is a poor indicator of outperformance, when combined with a decent valuation filter, Morningstar’s moat rating proves to be more than useful. Based on the available data, stocks with a wide-moat rating that also fit into the 4- or 5-star category deserve to be the subject of further analysis. See the detailed explanation and the underlying evidence of our first step in this article. W ...

Core Viewpoint - Agilent Technologies is well-positioned for long-term growth despite recent market challenges, supported by a diversified business model and multiple growth drivers [2][4][30]. Financial Performance - In 2023, Agilent reported $6.8 billion in revenue, achieving a four-year compound annual growth rate (CAGR) of 7% [3]. - The company has maintained a profitability margin of 27.4%, with an average margin growth of 100 basis points per year over the last four years [3][5]. - Earnings per share (EPS) have grown at an average rate of 15% annually over the past four years [3]. Business Diversification - Agilent's business is diversified, with 40% in instrumentation and 60% in services, consumables, diagnostic tests, and software [3][16]. - The company operates across six end markets, with pharmaceuticals being the largest, accounting for approximately 36% of total business [4][11]. Growth Strategy - Agilent aims for core revenue growth of 4% to 7% in the long term, with expectations for operating margin expansion of 50 to 100 basis points per year [4][5]. - The company has invested over $4.6 billion since 2015 to drive future growth, with $3 billion allocated to mergers and acquisitions [7][8]. Market Outlook - The total addressable market (TAM) for Agilent is estimated at $65 billion, with long-term growth prospects of 4% to 6% [9][10]. - Key growth drivers include advancements in human health, environmental sustainability, and food safety [10][23]. Segment Performance - The biopharma segment has shown resilience, with Agilent's biopharma business nearly doubling and now representing over 40% of total pharma business [17][19]. - The applied markets segment grew by 3% in 2023, driven by demand for PFAS testing and advanced materials [13][24]. Regional Growth - Agilent has experienced growth of 6% to 8% across five major geographies over the last four years, indicating strong local market strategies [15]. - The company anticipates a recovery in the Chinese market, projecting a return to growth by 2025 [60][65]. Innovation and Technology - Agilent is focusing on integrating AI into its operations and customer offerings to enhance efficiency and product development [25]. - The company is also investing in sustainability solutions, including refurbished products and environmentally friendly practices [26][27]. Future Guidance - For fiscal 2024, Agilent expects net revenue between $6.71 billion and $6.81 billion, with core revenue growth projected at 0.5% to 1% [29][39]. - The company remains committed to delivering leveraged earnings growth, aiming to grow earnings faster than revenue [29].

Summary of Agilent Technologies, Inc. Conference Call Company Overview - **Company**: Agilent Technologies, Inc. (NYSE:A) - **Conference Date**: January 9, 2024 - **Participants**: Mike McMullen (President & CEO), Bob McMahon (CFO), Rachel Vatnsdal (JPMorgan) Key Points Industry Context - 2023 was a challenging year for the life sciences tools and diagnostics industry, but Agilent views these challenges as transitory [2][33] - The company operates in a $65 billion total addressable market (TAM) with long-term growth prospects of 4% to 6% [9][10] Financial Performance - Agilent reported $6.8 billion in revenue for 2023, with a compound annual growth rate (CAGR) of 7% over four years [3] - Profitability is strong, with an operating margin of 27.4%, growing by an average of 100 basis points per year [3] - Earnings per share (EPS) have grown by an average of 15% annually over the last four years [3] Business Diversification - Agilent's business is diversified, with 40% in instrumentation and 60% in services, consumables, diagnostics, and software [3] - The largest end market is pharmaceuticals, accounting for 36% of total business, with double-digit growth over the last four years [4] Shareholder Value Creation - Agilent aims for core growth of 4% to 7% and operating margin expansion of 50 to 100 basis points per year [4][5] - The company has increased operating cash flow from over $500 million in 2015 to $1.8 billion in FY 2023, representing a CAGR of 17% [7] - Since 2015, Agilent has invested over $4.6 billion in growth initiatives, including $3 billion in M&A [7] Market Outlook - Agilent expects a return to growth in the pharma sector, which has been under pressure recently [41] - The company anticipates modest growth in chemical and advanced materials markets, with a focus on PFAS testing and advanced materials [22][24] Growth Drivers - Agilent is focusing on biopharma, with significant investments leading to a doubling of its biopharma business, now over 40% of total pharma revenue [17] - The company is also investing in cell analysis and diagnostics, with a $5 billion TAM expected to grow 5% to 7% [22] Geographic Expansion - Agilent has seen growth of 6% to 8% across five major geographies over the last four years [15] - The company is optimistic about long-term growth in China, despite short-term challenges [65] ESG and Sustainability - Agilent has set net-zero targets and has been recognized for its sustainability efforts, including a 33% reduction in carbon emissions since 2014 [26][27] M&A Strategy - Agilent is actively pursuing a "build-to-buy" growth strategy, with the potential for large acquisitions in the range of $4 billion to $5 billion [70] Guidance - For FY 2024, Agilent expects net revenue between $6.71 billion and $6.81 billion, with core revenue growth of 0.5% to 1% [29] Additional Insights - The company emphasizes a strong culture and teamwork as key to its success [28] - Agilent's CrossLab services business has grown significantly, contributing to a stable revenue stream [16][17] This summary encapsulates the key insights and financial metrics discussed during the conference call, highlighting Agilent's strategic focus, market positioning, and growth outlook.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company has again been included in the Dow Jones Sustainability World Index and the North America Index for its strong environmental, social, and governance (ESG) performance. “ It’s an honor to be named in the Dow Jones Sustainability Indices for a ninth consecutive year. I am particularly proud of our team’s progress in reducing emissions throughout our value chain and providing innovative solutions to help our ...

Core Viewpoint - Agilent Technologies has shown resilience despite short-term challenges, with a strong earnings report exceeding expectations and a notable stock performance, making it a compelling long-term investment opportunity [5][20]. Financial Performance - Q4 revenue was $1.69 billion, reflecting a 9.7% year-over-year decline, with an operating margin of 27.8% and earnings per share (EPS) of $1.38, surpassing analyst expectations of $1.34 [8][9]. - The Life Sciences and Applied Markets Group (LSAG) reported revenue of $928 million, an 18% core decline, attributed to cautious spending in the pharma sector [9][11]. - The company generated an operating cash flow of $516 million, exceeding 100% of adjusted net income, and announced a 4.9% dividend hike [12]. Market Segments - The pharma sector experienced a 14% decline, while biopharma outside China saw high single-digit growth [8][11]. - The Agilent CrossLab Group (ACG) achieved a revenue of $404 million, marking a 4% core increase, with double-digit growth in the Contract Services business [11]. - The Diagnostics and Genomics Group (DGG) generated revenue of $356 million, remaining flat on a core basis, with strong growth in Pathology offset by challenges in genomics [11]. Growth Outlook - Agilent anticipates a slow but steady recovery in fiscal year 2024, with projected revenue between $6.71 billion and $6.81 billion and non-GAAP EPS expected in the range of $5.44 to $5.55 [12]. - The company is optimistic about growth opportunities in China and emerging markets, aligning with local initiatives and focusing on the replacement cycle of small molecule instrumentation [13][14]. - Agilent's service business, represented by ACG, is expected to continue its double-digit growth, enhancing its comprehensive service offerings [15]. Valuation - Agilent is currently trading at a blended P/E ratio of 25.5x, with expectations of 10% annual EPS growth after 2024, indicating potential annual returns of 8% to 11% over the next few years [16].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________ Form 10-K _____________________________________________________________ (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended October 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For transition period from to Commission File Number: 001-15405 _____ ...